Needham reiterates Buy rating on Medtronic
Needham analyst Mike Matson has reiterated a Buy rating for Medtronic, maintaining a price target of $101.
*this image is generated using AI for illustrative purposes only.
Needham analyst Mike Matson has reaffirmed a Buy rating for Medtronic, maintaining a price target of $101. The endorsement reflects continued confidence in the medical device company's stock performance.
Analyst Rating
The rating reiteration comes as Medtronic trades on the NYSE under the ticker symbol MDT. The $101 price target suggests potential upside from current levels.
| Firm | Analyst | Rating | Price Target |
|---|---|---|---|
| Needham | Mike Matson | Buy | $101 |
What specific factors could drive Medtronic's stock to reach the $101 price target?
How might recent regulatory changes impact Medtronic's product pipeline and revenue growth?
What are the potential risks to Medtronic's market position from emerging competitors?
20
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
